Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity
Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quality research relevant to all aspects of drug design and discovery.
Corvus Pharmaceuticals, Inc.（纳斯达克股票代码：CRVS）一家处于临床阶段的生物制药公司，今天宣布了一项出版的临床前数据，重点展示了公司主导的ITk抑制剂计划soquelitinib对调节肿瘤免疫的潜力。这些数据发表在《npj药物发现》（Nature期刊组合中的一部分），这是一个致力于发布与药物设计和发现的各个方面相关的最高质量研究的开放获取的国际同行评审期刊。
The publication, entitled "Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity," includes a detailed overview of soquelitinib's mechanism of action – suppressing Th2 and Th17 cytokine production and sparing Th1 cytokines – that serves as a novel approach to cancer immunotherapy, both as a single agent and in combination with immune checkpoint inhibitors. The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function.
这篇名为《合成和表征soquelitinib的选择性ITk抑制剂以调节肿瘤免疫》的出版物包括了soquelitinib机制的详细概述——抑制Th2和Th17细胞因子的产生，并保存Th1细胞因子——这种独特的方法可作为癌症免疫治疗的一种新方法，无论是作为单一药物还是与免疫检查点抑制剂联合使用。数据还显示，soquelitinib增加了细胞毒性CD8阳性T细胞的效应功能，并导致记忆T细胞的增加，进而提高了其效应功能。
